Referenties

Mounjaro® Tirzepatide

Op deze pagina vind je een uitgebreide lijst met wetenschappelijke referenties die gebruikt zijn voor de artikelen in onze FAQ-sectie over Mounjaro® (tirzepatide). Deze bronnen zijn zorgvuldig geselecteerd via gerenommeerde databases zoals PubMed en andere wetenschappelijke platforms. De referenties zijn afkomstig uit vooraanstaande medische tijdschriften, wetenschappelijke publicaties en officiële gebruiksinstructies. Ze bieden een diepgaand inzicht in de effectiviteit, veiligheid en toepassing van Mounjaro® bij gewichtsmanagement.

Referenties

1. Semaglutide and Tirzepatide Use and Reduction of Cardiovascular Risks in Adults with Overweight and Obesity (2024). Medical Research Archives. Beschikbaar op: https://esmed.org/MRA/mra/article/view/5714

2. The Body weight Reducing Effects of Tirzepatide in People with and without Type 2 Diabetes (2024). Patient Preference and Adherence. Beschikbaar op: https://www.tandfonline.com/doi/abs/10.2147/PPA.S419304

3. Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo (2024). Endocrine. Beschikbaar op: https://link.springer.com/article/10.1007/s12020-024-03896-z

4. Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis (2024). Therapeutic Advances in Neurological Disorders. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11437580/

5. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity (2024). JAMA Intern Med. Beschikbaar op: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2821080

6. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials (2024). Diabetologia. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11153294/

7. One-year weight reduction with semaglutide or liraglutide in clinical practice (2024). JAMA Network Open. Beschikbaar op: https://jamanetwork.com/journals/jamanetworkopen/article-abstract/2823644

8. Productkenmerken (2024). Novo Nordisk. Beschikbaar op: https://www.ema.europa.eu/nl/documents/product-information/mounjaro-epar-product-information_nl.pdf

9. Mounjaro, Werkzame stof: tirzepatide (2024). Apotheek.nl. Beschikbaar op: https://www.apotheek.nl/medicijnen/tirzepatide?product=mounjaro

10. Mounjaro (2024). Eli Lilly. Beschikbaar op: https://mounjaro.lilly.com/

11. Highlights of Prescribing Information (2024). Eli Lilly. Beschikbaar op: https://pi.lilly.com/us/mounjaro-uspi.pdf?s=pi&redirect-referrer=https%3A%2F%2Fprotocol.bmi-clinic.com%2F

12. Productkenmerken (2024). Eli Lilly. Beschikbaar op: https://pi.lilly.com/us/mounjaro-us-ifu.pdf?s=ug0&redirect-referrer=https%3A%2F%2Fprotocol.bmi-clinic.com%2F

13. Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism (2024). Diabetes & Metabolism Journal. Beschikbaar op: https://www.e-dmj.org/journal/view.php?number=2843

14. Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials (2024). Frontiers in Public Health. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC10864442/

15. Safety and Effectiveness of Tirzepatide Use in Obesity Without Type 2 Diabetes Mellitus (2024). Cureus. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC10844768/

16. The Effect of Tirzepatide on Body Composition in People with Overweight and Obesity: A Systematic Review of Randomized, Controlled Studies (2024). Diseases. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11431103/

17. Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis (2024). Therapeutic Advances in Neurological Disorders. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11437580/

18. Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial (2024). Endocrine. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11445313/

19. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity (2024). JAMA Intern Med. Beschikbaar op: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2821080

20. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials (2024). Diabetologia. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11153294/

21. Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide (2024). Cardiovascular Diabetology. Beschikbaar op: https://cardiab.biomedcentral.com/articles/10.1186/s12933-024-02319-7

22. Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial (2024). Heart. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11420724/

23. Beyond glycemia: Comparing tirzepatide to GLP-1 analogues (2023). Reviews in Endocrine and Metabolic Disorders. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC10697893/

24. Glucagon‐like peptide agonists: A prospective review (2023). Endocrinology, Diabetes & Metabolism. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC10782143/

25. Obesity Management in Adults: A Review (2023). Journal of the American Medical Association. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC11325826/

26. A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications (2023). Life. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC10144237/

27. Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials (2023). International Journal of Molecular Sciences. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC10341852/

28. Beyond glycemia: Comparing tirzepatide to GLP-1 analogues (2023). Reviews in Endocrine and Metabolic Disorders. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC10697893/

29. The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities (2023). Current Obesity Reports. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC10748770/

30. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation (2023). The Lancet. Beschikbaar op: https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00059-7/fulltext

31. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (2023). Journal of the American Medical Association. Beschikbaar op: https://jamanetwork.com/journals/jama/fullarticle/2812936

32. Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1–4 (2023). Diabetes Care. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC10698219/

33. Tirzepatide Once Weekly for the Treatment of Obesity (2022). The New England Journal of Medicine. Beschikbaar op: https://www.nejm.org/doi/10.1056/NEJMoa2206038?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

34. Efficacy and safety of tirzepatide in patients with type 2 diabetes: A systematic review and meta-analysis (2022). Frontiers in Pharmacology. Beschikbaar op: https://pmc.ncbi.nlm.nih.gov/articles/PMC9774036/

35. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (2021). The New England Journal of Medicine. Beschikbaar op: https://www.nejm.org/doi/10.1056/NEJMoa2107519?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

DISCLAIMER

Betrouwbare informatie, verantwoord gedeeld

Samen op weg naar een gezonder leven – veilig, effectief en afgestemd op jouw doelen

De inhoud van deze referentielijst is uitsluitend bedoeld voor informatieve doeleinden. De vermelde artikelen en bronnen zijn gebaseerd op openbare wetenschappelijke publicaties en hebben betrekking op het gebruik van Mounjaro® en gerelateerde behandelingen. Hoewel we hebben gestreefd naar nauwkeurigheid en volledigheid, raden we aan om professioneel medisch advies in te winnen voordat u beslissingen neemt op basis van de inhoud van deze referenties. BMI Clinic aanvaardt geen aansprakelijkheid voor eventuele onjuistheden of onvolledigheden in de verstrekte informatie.

Voor meer achtergrondinformatie kan je de uitgebreide lijst op de pagina ‘Bronnen‘ raadplegen.